UBS AM
RCKT icon

UBS AM’s Rocket Pharmaceuticals RCKT Stock Holding History

UBS AM’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$893 Hold
261
– – ﹤0.01% 3621
2026
Q1 		$934 Buy
261
+169
+184% +$672 ﹤0.01% 3686
2025
Q4 		$323 Sell
92
-21,830
-100% -$74.7K ﹤0.01% 3254
2025
Q3 		$71.5K Sell
21,922
-264,390
-92% -$833K ﹤0.01% 2233
2025
Q2 		$701K Buy
286,312
+101,620
+55% +$515K ﹤0.01% 2450
2025
Q1 		$1.23M Buy
184,692
+45,120
+32% +$446K ﹤0.01% 2220
2024
Q4 		$1.75M Buy
139,572
+19,939
+17% +$300K ﹤0.01% 2116
2024
Q3 		$2.21M Buy
119,633
+1,561
+1% +$32K ﹤0.01% 1986
2024
Q2 		$2.54M Buy
118,072
+52,282
+79% +$1.2M ﹤0.01% 1869
2024
Q1 		$1.77M Sell
65,790
-5,221
-7% -$148K ﹤0.01% 1745
2023
Q4 		$2.13M Buy
71,011
+20,841
+42% +$460K ﹤0.01% 1662
2023
Q3 		$1.03M Buy
50,170
+18,499
+58% +$336K ﹤0.01% 1946
2023
Q2 		$543K Hold
31,671
– – ﹤0.01% 2287
2023
Q1 		$543K Sell
31,671
-21,800
-41% -$427K ﹤0.01% 2287
2022
Q4 		$1.05M Buy
53,471
+14,333
+37% +$264K ﹤0.01% 1831
2022
Q3 		$625K Hold
39,138
– – ﹤0.01% 2241
2022
Q2 		$539K Hold
39,138
– – ﹤0.01% 2276
2022
Q1 		$621K Hold
39,138
– – ﹤0.01% 2377
2021
Q4 		$854K Sell
39,138
-8,342
-18% -$228K ﹤0.01% 2298
2021
Q3 		$1.42M Sell
47,480
-1,372
-3% -$49.9K ﹤0.01% 1991
2021
Q2 		$2.16M Buy
48,852
+11,512
+31% +$500K ﹤0.01% 1806
2021
Q1 		$1.66M Buy
37,340
+1,869
+5% +$103K ﹤0.01% 1835
2020
Q4 		$1.95M Hold
35,471
– – ﹤0.01% 1698
2020
Q3 		$811K Buy
35,471
+4,080
+13% +$101K ﹤0.01% 1925
2020
Q2 		$657K Buy
+31,391
New +$566K ﹤0.01% 1995
2020
Q1 		– Sell
-9,414
Closed -$214K – 2518
2019
Q4 		$214K Buy
+9,414
New +$157K ﹤0.01% 2462
2019
Q3 		– Sell
-12,438
Closed -$187K – 2898
2019
Q2 		$187K Buy
+12,438
New +$217K ﹤0.01% 2558

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

UBS AM's RCKT Position: Q2 2026 in Review

UBS AM held its Rocket Pharmaceuticals (RCKT) position steady in Q2 2026 at 261 shares worth $893. The position accounts for ﹤0.01% of the portfolio, ranked #3621.

UBS AM first reported a position in RCKT in Q2 2019 and has held it in 27 quarters since. The position peaked at $2.54M in Q2 2024. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • UBS AM held 261 shares of Rocket Pharmaceuticals worth $893 as of Q2 2026.
  • UBS AM left its Rocket Pharmaceuticals share count unchanged in Q2 2026.
  • Rocket Pharmaceuticals made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3621 holding.
  • UBS AM first reported a position in Rocket Pharmaceuticals in Q2 2019 and has held it in 27 quarters since.
  • UBS AM's Rocket Pharmaceuticals position peaked at $2.54M in Q2 2024.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.